Impact Capital Partners LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Impact Capital Partners LLC acquired a new position in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,822 shares of the biopharmaceutical company’s stock, valued at approximately $287,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer during the 4th quarter worth about $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer during the 4th quarter worth about $28,000. Gladius Capital Management LP boosted its stake in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the period. Finally, Noble Wealth Management PBC purchased a new position in shares of Pfizer during the 4th quarter worth about $31,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday. UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Trading Down 0.4 %

NYSE PFE opened at $25.60 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market cap of $145.08 billion, a PE ratio of 18.16, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a 50 day moving average price of $26.26 and a 200 day moving average price of $27.17. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.10 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.